10,593
Views
5
CrossRef citations to date
0
Altmetric
Drug Evaluation

Dapagliflozin for the treatment of type 2 diabetes mellitus – an update

, ORCID Icon &
Pages 2303-2310 | Received 14 Apr 2021, Accepted 06 Jul 2021, Published online: 28 Jul 2021

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (2)

Hyun Chul Kim, Sangmi Lee, Siyoung Sung, Eunjin Kim, In-Jin Jang & Jae-Yong Chung. (2023) A Comparison of the Pharmacokinetics and Safety of Dapagliflozin Formate, an Ester Prodrug of Dapagliflozin, to Dapagliflozin Propanediol Monohydrate in Healthy Subjects. Drug Design, Development and Therapy 17, pages 1203-1210.
Read now
Ousman Bajinka, Kodzovi Sylvain Dovi, Lucette Simbilyabo, Ishmail Conteh & Yurong Tan. (2023) The predicted mechanisms and evidence of probiotics on type 2 diabetes mellitus (T2DM). Archives of Physiology and Biochemistry 0:0, pages 1-16.
Read now

Articles from other publishers (3)

Fatma Haddad, Ghadeer Dokmak, Maryam Bader & Rafik Karaman. (2023) A Comprehensive Review on Weight Loss Associated with Anti-Diabetic Medications. Life 13:4, pages 1012.
Crossref
Sabina Andreea Leancă, Irina Afrăsânie, Daniela Crișu, Iulian Theodor Matei, Ștefania Teodora Duca, Alexandru Dan Costache, Viviana Onofrei, Ionuţ Tudorancea, Ovidiu Mitu, Minerva Codruța Bădescu, Lăcrămioara Ionela Șerban & Irina Iuliana Costache. (2023) Cardiac Reverse Remodeling in Ischemic Heart Disease with Novel Therapies for Heart Failure with Reduced Ejection Fraction. Life 13:4, pages 1000.
Crossref
Zhenyu Bai, Ting Xie, Tianhao Liu, Zedong Chen, Linde Yu, Chao Zhang, Jincheng Luo, Liguo Chen, Xiaoshan Zhao & Ya Xiao. (2022) An integrated RNA sequencing and network pharmacology approach reveals the molecular mechanism of dapagliflozin in the treatment of diabetic nephropathy. Frontiers in Endocrinology 13.
Crossref